AIM ImmunoTech Provides Second Quarter 2021 Business Update

by Barry101 | Aug 17, 2021 | Press Release, Uncategorized

OCALA, Fla., Aug. 17, 2021 — AIM ImmunoTech Inc. (NYSE American: AIM) announces financial results for the second quarter ended June 30, 2021 and provides a business update.    Second Quarter 2021 Financial Highlights: As of June 30, 2021, AIM had cash,...

AIM CEO Thomas K. Equels Named to Board of Directors of BioFlorida Inc.

by Barry101 | Aug 16, 2021 | Press Release, Uncategorized

BioFlorida is the State’s Leading Life Sciences Industry AssociationOCALA, Fla., Aug. 16, 2021 — AIM ImmunoTech Inc. (NYSE American: AIM) today announced that CEO Thomas K. Equels has been appointed to the Board of Directors of BioFlorida Inc., the...

AIM ImmunoTech Announces Phase 2a Human Challenge Trial to Test its Drug Ampligen as an Intranasal Antiviral Prophylactic Therapy

by Barry101 | Jul 9, 2021 | Press Release, Uncategorized

Subjects will be exposed under controlled clinical facilities and medical monitoring to A/Perth/16/2009 (H3N2) or human rhinovirus (hRV-16) to gauge Ampligen’s effectiveness against those, and potentially other virusesOCALA, Fla., July 09, 2021 — AIM...

AIM ImmunoTech to Host Investor Update Webcast on Wednesday, July 14th at 11:00 AM ET

by Barry101 | Jul 6, 2021 | Press Release, Uncategorized

OCALA, Fla., July 06, 2021 — AIM ImmunoTech Inc. (NYSE American: AIM) today announced that it will host an investor update webcast at 11:00 a.m. Eastern Time on Wednesday, July 14, 2021, to discuss recent accomplishments and upcoming milestones. Investors and...

AIM ImmunoTech Completes All Treatments in Phase 1 Human Safety Study of Intranasal Administration of Ampligen

by Barry101 | Jun 21, 2021 | Press Release, Uncategorized

Company is Planning a Phase 2 Study of its Drug as a Broad-Spectrum Respiratory Virus ProphylaxisOCALA, Fla., June 21, 2021 — AIM ImmunoTech Inc. (NYSE American: AIM) today announced that all subjects have completed treatment in the Company’s Phase 1...